Effects on calcium phosphate homeostasis after sodium-glucose cotransporter 2 inhibitor in patients with advanced chronic kidney disease and type 2 diabetes mellitus.
Diabetes Res Clin Pract
; 216: 111818, 2024 Oct.
Article
in En
| MEDLINE
| ID: mdl-39128564
ABSTRACT
BACKGROUND:
The effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on calcium phosphate homeostasis in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) remain uncertain.METHODS:
A retrospective observational cohort study of patients with T2DM at CKD stage G3b-5ND who received SGLT2i as compared to control from 1 January 2015 through 31 December 2021 was recruited. Propensity score assignment at 13 ratio by logistic regression was done. All patients were followed for 12 months. Outcomes were changes in phosphate level.RESULTS:
We analyzed 1,450 SGLT2i users and 4,350 control subjects. At the 12th month, SGLT2i users had a slower increase in phosphate levels (absolute change -0.01 ± 0.28 vs + 0.14 ± 0.34 mmol/L; percentage change -0.74 % ± 25.56 vs + 10.88 ± 28.15 %, P for both < 0.001). The proportion of patients with high phosphate was lower with SGLT2i (8.2 % vs 24.6 % increase). In the generalized estimating equation, SGLT2i was linked to a longitudinal reduction in phosphate (B -0.039, P<0.001).CONCLUSIONS:
SGLT2i can effectively slow down the progression of phosphate retention in advanced CKD with T2DM.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Calcium Phosphates
/
Diabetes Mellitus, Type 2
/
Renal Insufficiency, Chronic
/
Sodium-Glucose Transporter 2 Inhibitors
/
Homeostasis
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Diabetes Res Clin Pract
Journal subject:
ENDOCRINOLOGIA
Year:
2024
Document type:
Article
Country of publication: